![]() |
Name |
[2-[(2S,4S)-4-[4-(benzylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] pentanoate
|
Molecular Formula | C39H43NO12 | |
IUPAC Name* |
[2-[(2S,4S)-4-[4-(benzylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] pentanoate
|
|
SMILES |
CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)C)O)NCC6=CC=CC=C6)O
|
|
InChI |
InChI=1S/C39H43NO12/c1-4-5-14-28(42)50-19-27(41)39(48)16-23-31(38(47)33-32(36(23)45)35(44)22-12-9-13-25(49-3)30(22)37(33)46)26(17-39)52-29-15-24(34(43)20(2)51-29)40-18-21-10-7-6-8-11-21/h6-13,20,24,26,29,34,40,43,45,47-48H,4-5,14-19H2,1-3H3/t20?,24?,26-,29?,34?,39-/m0/s1
|
|
InChIKey |
IUKSGXMOHXEUJY-VTNRTXQOSA-N
|
|
Synonyms |
N-Benzyladriamycin-14-valerate
|
|
CAS | NA | |
PubChem CID | 129691435 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 717.8 | ALogp: | 4.7 |
HBD: | 5 | HBA: | 13 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 198.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 52 | QED Weighted: | 0.103 |
Caco-2 Permeability: | -5.93 | MDCK Permeability: | 0.00000908 |
Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.997 |
Human Intestinal Absorption (HIA): | 0.326 | 20% Bioavailability (F20%): | 0.8 |
30% Bioavailability (F30%): | 0.315 |
Blood-Brain-Barrier Penetration (BBB): | 0.005 | Plasma Protein Binding (PPB): | 99.16% |
Volume Distribution (VD): | 1.06 | Fu: | 4.62% |
CYP1A2-inhibitor: | 0.151 | CYP1A2-substrate: | 0.441 |
CYP2C19-inhibitor: | 0.245 | CYP2C19-substrate: | 0.132 |
CYP2C9-inhibitor: | 0.579 | CYP2C9-substrate: | 0.728 |
CYP2D6-inhibitor: | 0.495 | CYP2D6-substrate: | 0.163 |
CYP3A4-inhibitor: | 0.18 | CYP3A4-substrate: | 0.759 |
Clearance (CL): | 14.861 | Half-life (T1/2): | 0.301 |
hERG Blockers: | 0.11 | Human Hepatotoxicity (H-HT): | 0.266 |
Drug-inuced Liver Injury (DILI): | 0.969 | AMES Toxicity: | 0.807 |
Rat Oral Acute Toxicity: | 0.128 | Maximum Recommended Daily Dose: | 0.933 |
Skin Sensitization: | 0.215 | Carcinogencity: | 0.717 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.612 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005541 | ![]() |
0.321 | D07IPB | ![]() |
0.747 | ||
ENC005540 | ![]() |
0.308 | D0T5XN | ![]() |
0.619 | ||
ENC000929 | ![]() |
0.303 | D07VLY | ![]() |
0.609 | ||
ENC005576 | ![]() |
0.291 | D0C9XJ | ![]() |
0.609 | ||
ENC005885 | ![]() |
0.286 | D01XWG | ![]() |
0.600 | ||
ENC001932 | ![]() |
0.284 | D0T8EH | ![]() |
0.525 | ||
ENC005572 | ![]() |
0.282 | D01XDL | ![]() |
0.519 | ||
ENC005539 | ![]() |
0.277 | D01UBX | ![]() |
0.339 | ||
ENC004290 | ![]() |
0.275 | D0G6VL | ![]() |
0.261 | ||
ENC005736 | ![]() |
0.275 | D01TSI | ![]() |
0.258 |